Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Chosen As One of the Top 50 MedTech Startups Transforming the Healthcare Industry
  • Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors
  • A Laser That Changes Everything
  • Novian Health Chosen as Red Herring Top 100 North America Winner
  • Discovering New Breast Cancer Treatments
  • Novian Health - Redefining Breast Care

NOVIAN HEALTH is a LEADING COMPANY IN IMAGE-GUIDED LASER TUMOR THERAPY

Its vision is to establish laser therapy as a treatment alternative to surgery for tumors, benefiting the patient. Currently Novian Health is focused on providing women with a minimally invasive alternative to surgery for cancerous and non-cancerous breast tumors. The Novilase laser procedure is performed in a breast center with ultrasound imaging guidance in a manner similar to a breast biopsy.

Other indications are also being explored.

Novian Health is bringing laser tumor therapy to market for early stage cancerous and benign breast tumors.

In Europe, Novian has received a CE Mark for treatment of malignant and benign breast tumors.  Post marketing clinical follow up will commence coincident with commercial launch.

In the U.S., FDA has granted Breakthrough Device designation to the Novilase Interstitial Laser System for the proposed indication for use: the focal destruction of malignant breast tumors in adult women who seek a breast conserving procedure. Novian Health will conduct the BR-003 confirmatory trial to collect data in support of U.S. marketing clearance for focal destruction of malignant tumors of the breast.

Novilase is FDA 510(k) cleared for treatment of benign breast tumors and soft tissue ablation.  A post-marketing registry comprising benign breast tumors is ongoing with patients being treated at centers in the U.S. and soon Europe.

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by